Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is experiencing a positive surge in its stock price, reflecting investor confidence amid strong earnings outlooks.
Regeneron Pharmaceuticals Inc. is rising today, with shares up by 1.46% to close at CA$761.47. This uptick comes as the company continues to garner attention for its robust fundamentals and positive earnings revisions.
Investor takeaway: With a strong Zacks Rank of #1 (Strong Buy) and favorable valuation metrics, Regeneron appears to be an attractive option for value investors looking for growth in the biomedical sector.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$77.45B
P/E
19.5x
Div. yield
0.46%
Div. / share
$3.64
52W high
$859.34
52W low
$538.24
1W change
-6.64%
Beta
0.19
Analyst Price Targets
Based on 25 analysts covering REGN · as of Sep 25, 2026
Wall Street analysts forecast REGN stock price to rise 13.4% over the next 12 months.
Consensus
Buy4.28 / 5.00
Avg. Target
C$850.88
+13.4% Upside
Previously C$849.32 on Sep 17, 2026
Current Price
C$750.51
Last close
Analyst Breakdown (25 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
29.6%
Annualized
90-Day Vol
30.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$897.24
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$796.54 | C$719.23 – C$882.16 |
| 60 trading days | C$845.39 | C$731.73 – C$976.71 |
| 90 trading days | C$897.24 | C$751.81 – C$1070.80 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
1.46% Increase in Stock Price
Regeneron's stock price rose by 1.46% today, reflecting investor optimism driven by strong earnings revisions and favorable comparisons to competitors.
Bull case
Regeneron's strong earnings estimate revisions and favorable valuation metrics, including a forward P/E ratio of 14.16, suggest that the stock may be undervalued at its current price levels. This indicates a potential for growth, making it appealing for investors seeking value in the biomedical sector.
Bear case
Despite the positive momentum, potential market volatility and competition from emerging therapies could pose risks to Regeneron's future performance. Investors should keep an eye on these factors as they could impact the company's market position and growth prospects.
Strong Earnings Outlook
Advertisement
Regeneron has recently seen positive revisions to its earnings estimates, with projections for 2026 earnings per share rising from $46.55 to $53.11. This trend indicates that analysts are optimistic about the company's future profitability.
Valuation Metrics Favorable
With a forward P/E ratio of 14.16 and a PEG ratio of 1.23, Regeneron is positioned favorably compared to its peers. These metrics suggest that the stock may be undervalued, attracting interest from value-focused investors.
Market Position and Competition
Regeneron remains a leader in the biopharmaceutical sector, particularly with its established therapies like Eylea. However, it faces increasing competition from emerging treatments, which could impact its market share and growth prospects.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
